Eversept Partners, LP Cyclerion Therapeutics, Inc. Transaction History

Eversept Partners, LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.47 - $1.29 $174,818 - $479,821	-371,955 Closed	0 $0
Q1 2022 Nov 08, 2023	BUY	$0.96 - $1.78 $357,076 - $662,079	371,955 New	371,955 $412,000
Q3 2021 Nov 08, 2023	BUY	$2.73 - $4.13 $1.02 Million - $1.54 Million	371,955 New	371,955 $1.14 Million
Q3 2021 Nov 15, 2021	BUY	$2.73 - $4.13 $339,317 - $513,325	124,292 Added 50.19%	371,955 $1.14 Million
Q2 2020 Nov 08, 2023	SELL	$2.37 - $7.14 $212,072 - $638,901	-89,482 Reduced 26.54%	247,663 $1.46 Million
Q2 2020 Aug 13, 2020	SELL	$2.37 - $7.14 $212,072 - $638,901	-89,482 Reduced 26.54%	247,663 $1.46 Million
Q1 2020 Nov 08, 2023	BUY	$2.46 - $5.84 $782,821 - $1.86 Million	318,220 Added 1681.48%	337,145 $893,000
Q1 2020 May 13, 2020	BUY	$2.46 - $5.84 $829,376 - $1.97 Million	337,145 New	337,145 $893,000
Q3 2019 Nov 13, 2019	SELL	$8.12 - $14.54 $153,670 - $275,169	-18,925 Closed	0 $0
Q2 2019 Nov 08, 2023	BUY	$9.6 - $22.85 $181,680 - $432,436	18,925 New	18,925 $216,000
Q2 2019 Aug 13, 2019	BUY	$9.6 - $22.85 $181,680 - $432,436	18,925 New	18,925 $217,000

293K

Ticker CYCN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,479,800
Market Cap $139M
Description
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of...

Get notified when there are updates to the investment portfolio of Eversept Partners, LP, based on Form 13F filings with the SEC.

Stay updated on Eversept Partners, LP with notifications on news.